Evidence map›Paper›PMID 28386965›Full record

ArticleCancer2017

Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients.

Timothy L Fitzgerald, Jimmy T Efird, Nelly Bellamy, Suzanne M Russo, Charulata Jindal, Catalina Mosquera, Elizabeth G Holliday, Tithi Biswas

Open access · bronzeAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Honokiol Suppression of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Cell Biological Activity and Its Mechanism.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Timothy L FitzgeraldSurgical Oncology, Maine Medical Center Cancer Institute, Scarborough, Maine.
Jimmy T EfirdSchool of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.ORCID http://orcid.org/0000-0002-4890-5111
Nelly BellamyDepartment of Surgical Oncology, Brody School of Medicine, East Carolina University, Greenville, North Carolina.
Suzanne M RussoDepartment of Radiation Oncology, University Hospitals, Case Western Reserve University, Cleveland, Ohio.
Charulata JindalSchool of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.
Catalina MosqueraDepartment of Surgical Oncology, Brody School of Medicine, East Carolina University, Greenville, North Carolina.
Elizabeth G HollidaySchool of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.
Tithi BiswasDepartment of Radiation Oncology, University Hospitals, Case Western Reserve University, Cleveland, Ohio.
East Carolina University · USUniversity Hospitals of Cleveland · USUniversity of Newcastle Australia · AUMaine Medical Center · USVidant Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBoth perioperative chemotherapy (PECT) and postoperative chemoradiotherapy (POCRT) have a significant survival advantage over surgery alone for the treatment of patients with gastric cancer. However, to the best of our knowledge, these regimens have not been compared in a randomized clinical trial. The purpose of the current observational study was to compare overall survival among patients receiving PECT versus POCRT for the treatment of gastric/gastroesophageal junction (GEJ) adenocarcinomas.

methodsPatients with resected clinical American Joint Committee on Cancer TNM stage II or III adenocarcinomas of the stomach or GEJ from 2004 through 2013 were identified utilizing the National Cancer Data Base. Hazard ratios (HRs), 95% confidence intervals, and P values were computed using a Cox proportional hazards procedure. Multivariable models were adjusted for treatment regimen, age, race, ethnicity, tumor size, TNM stage, Charlson comorbidity index, and tumor grade.

resultsPatients receiving PECT had a 72% survival advantage compared with those treated with POCRT (5058 patients; HR, 0.58 [adjusted P<.0001]). The 5-year actuarial survival rate for PECT was 44% compared with 38% for POCRT. A statistically significant survival advantage for PECT also was observed when the analysis was stratified by clinical stage of disease (stage II [3192 patients]: adjusted HR, 0.79 [P = .041]; and stage III [1866 patients]: adjusted HR, 0.49 [P<.0001]). This benefit was greatest among patients with lymph node-positive disease who converted to lymph node-negative status with PECT.

conclusionsIn this large series of patients with stage II/III resected gastric/GEJ adenocarcinomas from >1500 American College of Surgeons Commission on Cancer-accredited facilities, patients receiving PECT were shown to survive longer than those receiving POCRT. Cancer 2017;123:2909-17. © 2017 American Cancer Society.

Indexed as

Chemoradiotherapy, AdjuvantChemotherapy, AdjuvantDigestive System Surgical ProceduresEsophagogastric JunctionNeoadjuvant TherapyAdenocarcinomaAgedAntineoplastic Combined Chemotherapy ProtocolsDatabases, FactualFemaleHumansMaleMiddle AgedMultivariate AnalysisNeoplasm StagingPerioperative Careadenocarcinomagastric cancergastroesophageal junctionperioperative chemotherapypostoperative chemoradiotherapy

Identifiers

PMID28386965
OpenAlexW2604302262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.